Howard, Frederick M. http://orcid.org/0000-0002-6039-1141
Dolezal, James http://orcid.org/0000-0002-6788-7203
Kochanny, Sara
Khramtsova, Galina http://orcid.org/0000-0001-9625-1549
Vickery, Jasmine
Srisuwananukorn, Andrew http://orcid.org/0000-0002-8736-8726
Woodard, Anna
Chen, Nan
Nanda, Rita http://orcid.org/0000-0001-5248-0876
Perou, Charles M. http://orcid.org/0000-0001-9827-2247
Olopade, Olufunmilayo I. http://orcid.org/0000-0002-9936-1599
Huo, Dezheng http://orcid.org/0000-0002-4041-1678
Pearson, Alexander T. http://orcid.org/0000-0003-2801-7456
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (K08-DE026500)
U.S. Department of Defense (BC211095P1, BC211095P1)
Conquer Cancer Foundation (2022YIA-6675470300)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (F32CA265232, 1P20-CA233307, P50-CA058223, 1P20-CA233307, 1P20-CA233307)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Breast Cancer Research Foundation (BCRF-21-071, BCRF-21-071)
Susan G. Komen (SAC 210203)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 7 September 2022
Accepted: 30 March 2023
First Online: 14 April 2023
Competing interests
: F.M.H., S.K., G.K., J.V., A.S., A.W., N.C. and D.H. report no competing financial or non-financial conflicts of interest. J.D. reports consulting fees from MJH Life Sciences. R.N. reports contracted research with Arvinas, AstraZeneca, Celgene, Corcept Therapeutics, Genentech/Roche, Immunomedics, Merck, OBI Pharma, Odonate Therapeutics, OncoSec, Pfizer, Seattle Genetics, and Taiho and consulting fees from AstraZeneca, BeyondSpring, Cardinal Health, Fujifilm, Immunomedics/Gilead, Infinity, iTeos, Merck, OBI, Oncosec, and Seagen. C.M.P. reports ownership interest and royalties from Bioclassifier LLC. O.I.O reports ownership interest in 54Gene, CancerIQ, and Tempus and financial interest in Color Genomics, Healthy Life for All Foundation, and Roche/Genetech. A.T.P reports consulting fees from Prelude Biotherapeutics, LLC, Ayala Pharamceuticals, Elvar Therapeutics, Abbvie, and Privo, and contracted research with Kura Oncology and Abbvie.